Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17107455 | 0.83 | MAOB (0.44) | TP53MAPTSMN1; SMN2EPHX2MTNR1B | |
| SCHEMBL21116465 | 0.83 | TP53 (0.46) | TP53MAPTSMN1; SMN2EPHX2MTNR1B | |
| SCHEMBL21116466 | 0.81 | TP53 (0.46) | TP53MAPTSMN1; SMN2EPHX2MTNR1B | |
| SCHEMBL18014739 | 0.81 | TP53 (0.41) | TP53MAPTSMN1; SMN2EPHX2MTNR1B | |
| SCHEMBL18015849 | 0.81 | MTNR1A (0.45) | TP53MAPTSMN1; SMN2MTNR1BHTR1A | |
| SCHEMBL9844197 | 0.75 | PTPN1 (0.47) | MAPTSMN1; SMN2HTR1AHTR1DHTR2C | |
| SCHEMBL29592044 | 0.75 | PTPN1 (0.47) | MAPTSMN1; SMN2HTR1AHTR1DHTR2C | |
| SCHEMBL17324189 | 0.74 | MTNR1A (0.40) | TP53MAPTSMN1; SMN2MTNR1BPPARD | |
| SCHEMBL30956100 | 0.74 | TP53 (0.40) | TP53MAPTSMN1; SMN2MTNR1BPPARD | |
| SCHEMBL20274083 | 0.74 | EPHX2 (0.41) | TP53MAPTSMN1; SMN2EPHX2MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110035993-A | SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS | 艾伯维公司 | 2019-07-19 | — | — | CN | disclosed |
| EP-3052495-B1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3052495-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | Pfizer Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049616-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | TP53 2499/4885MAPT 358/4885SMN1; SMN2 1127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.